SELLAS Life Sciences (SLS) stock soars 255% YTD as Phase 3 AML trial hits critical milestone. Analysts set $10 target amid rising institutional interest. The post SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress appeared first on Blockonomi.